摘要
目的探讨异黏蛋白(MTDH)在原发性肝癌组织中的表达及其临床意义。方法收集原发性肝癌患者手术切除标本66例,用癌旁正常组织作为对照,运用免疫组化技术检测肝癌组织及对照正常肝组织中MTDH的表达水平,统计学方法分析其与患者临床参数的关系。结果在66例肝癌组织中MTDH阳性表达率为77.3%(51/66),对照组MTDH阳性表达率为34.8%(23/66例),两者比较,差异有显著性(P<0.001);在原发性肝癌组织中,MTDH的表达水平在肝癌患者不同性别、年龄、AST、AFP及肿瘤大小等临床病理特征中表达差异无显著性(P>0.05),MTDH的表达随着肝癌患者临床分期进展而呈上升趋势(P<0.05);MTDH的表达与肝癌患者HBV感染相关,HBV阳性肝癌患者的MTDH表达高于HBV阴性肝癌患者(P<0.05)。结论 MTDH在原发性肝癌组织中表达上调,其可能成为肝癌患者病情进展预测的潜在生物学标志。
Objective To investigate the expression and clinical significance of MTDH in primary hepatocellular carcinoma tissues. Methods 66 primary hepatocellular carcinoma tissues and normal liver tissues near the cancer were collected from Mar 2007 to Mar 2014. Immunohistochemistry was used to detect the expression of MTDH. Results The positive expression rate of MTDH was 77.3% in primary hepatocellular carcinoma tissues and 34.8% in normal liver tissues.The upregulation of MTDH expression was associated with the progression of clinical stage and HBV. Conclusions The upgrade expression of MTDH is probably a significant event in the primary hepatocellular carcinoma,and it could be regarded as a potential biomarker in predicting the progression in primary hepatocellular carcinoma.
出处
《中南医学科学杂志》
CAS
2017年第3期295-298,共4页
Medical Science Journal of Central South China
关键词
MTDH
原发性肝癌
免疫组化技术
hepatocellular carcinoma
MTDH
immunohistochemistry
clinical significance
